Physician profile
Ananth Srinivasan
NPI 1053625616
$3,743.06
in general payments reported to CMS, 2019-2025
13 companies · $3,238 in 2025
The $3,238 reported for 2025 was more than what 86% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $88.94 · 2021: $88.92 · 2022: $131 · 2023: $129 · 2024: $67.67 · 2025: $3,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,864 · Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,864.29 |
| Food and Beverage | $569.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organox LTD | $2,895.29 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $380.64 | 2020-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $192.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $79.37 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.31 | 2025 | Livtencity |
| Merck Sharp & Dohme LLC | $30.07 | 2024 | Prevymis |
| Ethicon US, LLC | $28.98 | 2025 | Echelon Flex |
| Intercept Pharmaceuticals, INC. | $26.79 | 2021-2022 | |
| Mirum Pharmaceuticals, INC. | $18.64 | 2025 | Livmarli |
| Mallinckrodt Hospital Products INC. | $17.59 | 2023 | Terlivaz |
| Dova Pharmaceuticals | $14.80 | 2021 | |
| Medtronic, INC. | $13.84 | 2022 | |
| Sobi, INC | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananth Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.